Sachin Jain, an analyst from Bank of America Securities, reiterated the Buy rating on AstraZeneca. The associated price target remains the same with p14,500.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sachin Jain has given his Buy rating due to a combination of factors including AstraZeneca’s strong financial performance and promising pipeline. The company reported a notable 4% earnings per share beat and a 3% sales beat for the third quarter of 2025, demonstrating effective cost control and operational efficiency. The unchanged guidance for fiscal year 2025 suggests confidence in continued growth, with expected EPS growth of 10-12% and sales growth of 8-9%.
Moreover, AstraZeneca’s robust pipeline, with significant upcoming data reads, supports a positive outlook. The valuation appears attractive with a projected price-to-earnings ratio of 16x for 2026, with potential for rerating to 18x. Key developments in oncology and cardiovascular products, alongside strategic advancements in rare diseases, further bolster the investment case, positioning AstraZeneca well for sustained growth and market leadership.
According to TipRanks, Jain is a 3-star analyst with an average return of 1.8% and a 57.75% success rate. Jain covers the Healthcare sector, focusing on stocks such as GlaxoSmithKline, Novartis AG, and Sanofi.
In another report released on October 31, UBS also maintained a Buy rating on the stock with a £142.00 price target.